A review of research about Trikafta and mental health: a report from Cystic Fibrosis Foundation’s Prioritizing Research in Mental Health Working Group
Elexacaftor/tezacaftor/ivacaftor can be effective for people with cystic fibrosis with the 3849 gene variant
Differences between the United States and the European Union in the time of approval of CFTR modulators for the treatment of cystic fibrosis
Correlation between trough concentration and exposure during the day for elexacaftor, tezacaftor and ivacaftor
Changes in cholesterol levels in people with cystic fibrosis after starting highly effective modulators
Changes in pancreatic enzyme function for children with cystic fibrosis while taking modulators (Trikafta®, Orkambi®, Symdeco®, and Kalydeco®)
